About this trial
This phase IV trial studies whether low dose aspirin can be used to lower inflammation and prevent endometrial cancer in postmenopausal women with changes in the endometrial tissue that are not related to thinning (non-atrophic endometrial changes) and pain. As people age, there is an accumulation of fats, cell death, and inflammation, which causes a surge of pro-cancer-causing events. It is thought that there are several factors involved in the development of endometrial cancer, but that managing the inflammation may address the root cause. Low dose aspirin is aspirin that contains a lower dose than a standard adult tablet. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. Aspirin belongs to the family of drugs called nonsteroidal anti-inflammatory agents. It is also being studied in cancer prevention. Giving low dose aspirin may be an effective way to lower inflammation and prevent endometrial cancer in postmenopausal women with non-atrophic endometrial changes and pain.
Eligibility criteria
Qualifiers
PRE-REGISTRATION: Postmenopausal women
PRE-REGISTRATION: Transvaginal ultrasound
PRE-REGISTRATION: Scheduled endometrial biopsy
PRE-REGISTRATION: Provide risk factor survey
Disqualifiers
PRE-REGISTRATION: Not postmenopausal person born with uterus
PRE-REGISTRATION: Atrophic endometrium
PRE-REGISTRATION: No uterus
PRE-REGISTRATION: Malignancy found
Trial design
Treatments tested in this trial
- Biospecimen Collection
- Low-Dose Aspirin
- Patient Observation
- Questionnaire Administration
- Ultrasound Imaging